NOACs demonstrated comparable in-hospital mortality rates (7.2%) to warfarin (7.8%) in patients presenting to the emergency department with gastrointestinal bleeding.
Cross-Sectional (n=299)
No
Do NOACs improve short-term clinical outcomes compared to warfarin in anticoagulated patients with GI bleeding?
Absolute Event Rate: 7.2% vs 7.8%
p-value: p=0.855
zAma: Gastrointestinal (GI) kanama, oral antikoaglan tedavisinin nemli bir komplikasyonudur.Vitamin K iermeyen oral antikoaglanlar (NOAC) warfarine gre avantajlar sunsa da antikoaglan tedavisi gren hastalarda GI kanama olaylarn takiben ksa vadeli klinik sonular karlatran snrl sayda gerek dnya verisi bulunmaktadr.Warfarin veya NOAC tedavisi gren ve GI kanamas geiren hastalarn klinik zelliklerini, mdahale gereksinimlerini, hastaneye yat sonularn ve mortaliteyi karlatrmak ve bireysel NOAC ajanlar arasndaki farklar aratrmaktr
Sorgun et al. (Thu,) conducted a cross-sectional in Gastrointestinal bleeding on oral anticoagulants (n=299). NOACs vs. Warfarin was evaluated on In-hospital mortality (p=0.855). NOACs demonstrated comparable in-hospital mortality rates (7.2%) to warfarin (7.8%) in patients presenting to the emergency department with gastrointestinal bleeding.